Oragenics Inc (NYSEAMERICAN:OGEN) was the recipient of a large growth in short interest in December. As of December 31st, there was short interest totalling 1,064,412 shares, a growth of 27.5% from the December 14th total of 834,965 shares. Currently, 4.2% of the shares of the stock are short sold. Based on an average daily volume of 1,296,191 shares, the short-interest ratio is currently 0.8 days.
OGEN opened at $1.00 on Friday. Oragenics has a one year low of $0.38 and a one year high of $4.20.
Oragenics (NYSEAMERICAN:OGEN) last released its quarterly earnings results on Tuesday, November 13th. The biotechnology company reported ($0.35) EPS for the quarter, missing analysts’ consensus estimates of ($0.22) by ($0.13).
Oragenics, Inc focuses on developing antibiotics against infectious diseases and treatments for oral mucositis. It is developing OG716, an antibiotic product candidate, which is in nonclinical testing for healthcare-associated infections, as well as other homolog antibiotic product candidates. The company is also developing AG013, which is in Phase II clinical trial for the treatment of oral mucositis in cancer patients.
Featured Article: What factors cause inflation to rise?
Receive News & Ratings for Oragenics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oragenics and related companies with MarketBeat.com's FREE daily email newsletter.